CN102548555A - 用于治疗帕金森病的组合物和方法 - Google Patents

用于治疗帕金森病的组合物和方法 Download PDF

Info

Publication number
CN102548555A
CN102548555A CN2010800342070A CN201080034207A CN102548555A CN 102548555 A CN102548555 A CN 102548555A CN 2010800342070 A CN2010800342070 A CN 2010800342070A CN 201080034207 A CN201080034207 A CN 201080034207A CN 102548555 A CN102548555 A CN 102548555A
Authority
CN
China
Prior art keywords
dopamine
days
receptor
disease
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800342070A
Other languages
English (en)
Chinese (zh)
Inventor
P·西曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clera Inc
Original Assignee
Clera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clera Inc filed Critical Clera Inc
Publication of CN102548555A publication Critical patent/CN102548555A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800342070A 2009-07-31 2010-07-30 用于治疗帕金森病的组合物和方法 Pending CN102548555A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23026409P 2009-07-31 2009-07-31
US61/230,264 2009-07-31
PCT/CA2010/001185 WO2011011886A1 (en) 2009-07-31 2010-07-30 Compositions and methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
CN102548555A true CN102548555A (zh) 2012-07-04

Family

ID=43528672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800342070A Pending CN102548555A (zh) 2009-07-31 2010-07-30 用于治疗帕金森病的组合物和方法

Country Status (12)

Country Link
US (1) US9192605B2 (https=)
EP (1) EP2459194A4 (https=)
JP (1) JP5756105B2 (https=)
KR (1) KR20120103557A (https=)
CN (1) CN102548555A (https=)
AU (1) AU2010278645A1 (https=)
BR (1) BR112012008193A2 (https=)
CA (1) CA2769149A1 (https=)
IL (1) IL217149A0 (https=)
MX (1) MX2012001290A (https=)
NZ (1) NZ598247A (https=)
WO (1) WO2011011886A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884064A (zh) * 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN114601928A (zh) * 2022-04-02 2022-06-10 首都医科大学 一种钙超载介导神经元死亡的标志物及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6371716B2 (ja) * 2014-04-01 2018-08-08 東京エレクトロン株式会社 基板液処理装置及び基板液処理方法並びに基板液処理プログラムを記録したコンピュータ読み取り可能な記録媒体
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147613A1 (en) * 2001-03-09 2004-07-29 Ralph Dawirs Use of neuroactive substances for the treatment of parkinsons disease and pharmaceutical combination
CN1681491A (zh) * 2002-09-17 2005-10-12 默塔克神经科学有限公司 运动障碍的治疗
WO2006047861A1 (en) * 2004-11-03 2006-05-11 Clera Inc. Method to detect dopamine receptors in the functional d2high state
CN1802153A (zh) * 2002-10-22 2006-07-12 药物滥用科学研究公司 用选择性多巴胺d1受体激动剂治疗认知损害

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма
US20010056101A1 (en) * 1998-06-29 2001-12-27 Carol A. Tamminga Use of dopamine receptor antagonists in combination with partial dopamine agonist to prevent tolerance in treating nervous disorders related to dopamine dysfunction
AU2009212065B2 (en) * 2008-02-05 2014-03-20 Clera Inc. Compositions and methods for alleviating depression or improving cognition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040147613A1 (en) * 2001-03-09 2004-07-29 Ralph Dawirs Use of neuroactive substances for the treatment of parkinsons disease and pharmaceutical combination
CN1681491A (zh) * 2002-09-17 2005-10-12 默塔克神经科学有限公司 运动障碍的治疗
CN1802153A (zh) * 2002-10-22 2006-07-12 药物滥用科学研究公司 用选择性多巴胺d1受体激动剂治疗认知损害
WO2006047861A1 (en) * 2004-11-03 2006-05-11 Clera Inc. Method to detect dopamine receptors in the functional d2high state

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884064A (zh) * 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
US11147820B2 (en) 2012-12-24 2021-10-19 Neurogastrx, Inc. Methods for treating GI tract disorders
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US11390620B2 (en) 2020-04-02 2022-07-19 Neurogastrx, Inc. Polymorphic forms of metopimazine
US11834445B2 (en) 2020-04-02 2023-12-05 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN114601928A (zh) * 2022-04-02 2022-06-10 首都医科大学 一种钙超载介导神经元死亡的标志物及应用

Also Published As

Publication number Publication date
WO2011011886A1 (en) 2011-02-03
BR112012008193A2 (pt) 2016-03-01
EP2459194A1 (en) 2012-06-06
MX2012001290A (es) 2012-06-12
KR20120103557A (ko) 2012-09-19
IL217149A0 (en) 2012-02-29
JP2013500943A (ja) 2013-01-10
US9192605B2 (en) 2015-11-24
CA2769149A1 (en) 2011-02-03
US20120115910A1 (en) 2012-05-10
JP5756105B2 (ja) 2015-07-29
EP2459194A4 (en) 2012-12-19
NZ598247A (en) 2014-01-31
AU2010278645A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
US11608339B2 (en) 5-HT2C receptor agonists and compositions and methods of use
US20100298382A1 (en) Compositions and methods for alleviating depression or improving cognition
BR112017023088B1 (pt) Compostos agonistas do receptor 5-ht2c, composição farmacêutica,seu processo de preparação e seus usos
SK15772002A3 (sk) Deriváty apomorfínu, ich použitie a farmaceutická kompozícia s ich obsahom
EP3806835A1 (en) Compositions and methods for treating respiratory depression with fenfluramine
US9782404B2 (en) Methods of treating disease-induced ataxia and non-ataxic imbalance
CN102548555A (zh) 用于治疗帕金森病的组合物和方法
RU2413512C1 (ru) Средство, обладающее каппа-опиоидной агонистической активностью
KR20150029713A (ko) 투렛 증후군의 치료를 위한 융합된 벤즈아제핀
AU2003267557B2 (en) Treatment of dyskinesia
JPH05500958A (ja) 神経保護剤用イミノメタノジベンゾ（ａ，ｄ）シクロヘプテン誘導体
JP4864259B2 (ja) 性機能障害および血管収縮に関する疾患の予防および治療におけるイカリンの使用
JPH0211543A (ja) 脳血管剤として有用な多環式アミン誘導体
HK1172275A (en) Compositions and methods for treating parkinson's disease
JP6448990B2 (ja) 薬物依存症の治療薬としてのＴｒｋＢ受容体拮抗薬
CN104619323B (zh) 用于在治疗性功能障碍中使用的a3腺苷受体配体
RU2761219C2 (ru) Терапевтическое средство от расстройств, связанных с употреблением алкоголя
Kapitsa et al. P. 5.006 Electrophysiological analysis of the hemantane effects in rats with MPP+-induced parkinsonism
EP1815854A1 (en) Treatment of dyskenesia
HK1209342B (en) A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172275

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120704

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1172275

Country of ref document: HK